1345848-22-7

Upstream product

• 1345848-20-5 (R)-N-(4-((2-(2-(benzyloxy)propanamido)pyridin-4-yl)oxy)-2,5-difluorophenyl)-N'-(4-fluorophenyl)cyclopropane1,1-dicarboxamide 
• 1345848-02-3 tert-butyl [4-(2,5-difluoro-4-{[1-(4-fluorophenylcarbamoyl)cyclopropanecarbonyl]amino}phenoxy)pyridin-2-yl]carbamate 
• 1345847-77-9 N-[4-(2-chloropyridin-4-yloxy)-2,5-difluorophenyl]-N'-[4-fluorophenyl]cyclopropane-1,1-dicarboxamide 
• 1225278-65-8 4-((2-chloropyridin-4-yl)oxy)-2,5-difluoroaniline 
• 1225278-64-7 2-chloro-4-(2 ,5-difluoro-4-nitrophenoxy)pyridine 
• 1345847-71-3 methyl 1-((4-fluorophenyl)amidomethyl)cyclopropyl-1-carboxylate 
• 928038-40-8 N-(4-{[2-Aminopyridin-4-yl)oxy]-2,5-difluorophenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 
• 849217-48-7 ((4-fluorophenyl)carbamoyl)cyclopropanecarboxylic acid 
• 113020-21-6 1,1-cyclopropanedicarboxylic acid monomethyl ester 
• 17368-12-6 2-chloropyridin-4-ol 
• 2105-61-5 1,2,4-trifluoro-5-nitrobenzene 
• 371-40-4 4-fluoroaniline 

Relevant academic research and scientific papers

CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITES

The disclosed compounds are useful in the treatment of mammalian cancers and especially human cancers. Compounds, pharmaceutical compositions, and methods of Formula I are disclosed: Formula I or a pharmaceutically acceptable salt, hydrate, solvate, enantiomer, stereoisomer, or tautomer thereof.